Global Patent Index - EP 0584251 A4

EP 0584251 A4 19950802 - CYTOKINE RECEPTOR TARGETED MOLECULES FOR TREATMENT OF MEOPLASTIC CELL GROWTH.

Title (en)

CYTOKINE RECEPTOR TARGETED MOLECULES FOR TREATMENT OF MEOPLASTIC CELL GROWTH.

Title (de)

GEGEN DEN CYTOKIN-REZEPTOR GERICHTETE MOLEKÜLE ZUR BEHANDLUNG DES NEOPLASMATISCHEN ZELLWACHSTUMS.

Title (fr)

MOLECULES CIBLEES SUR UN RECEPTEUR DE CYTOKINE PAR LE TRAITEMENT DE LA CROISSANCE DE CELLULES NEOPLASIQUES.

Publication

EP 0584251 A4 19950802 (EN)

Application

EP 92912726 A 19920515

Priority

US 70193291 A 19910517

Abstract (en)

[origin: WO9220364A1] The invention features a method for treating meoplastic cell growth in a patient, wherein the meoplastic cell is of non-lymphoid and non-monocytic origin. The method includes administering to the patient a molecule which is capable of specifically binding to a cytokine receptor expressed on the meoplastic cell, which molecule is capable of decreasing the viability of the meoplastic cell. The cytokine receptor is a receptor normally expressed on cells of lymphoid or monocytic origin.

IPC 1-7

A61K 37/02; A61K 37/24

IPC 8 full level

A61K 38/00 (2006.01); A61K 39/395 (2006.01); A61K 47/48 (2006.01); A61P 35/00 (2006.01); C07K 14/245 (2006.01); C07K 14/34 (2006.01); C07K 14/54 (2006.01); C07K 14/55 (2006.01); C07K 19/00 (2006.01)

CPC (source: EP)

A61K 47/62 (2017.07); A61K 47/6813 (2017.07); A61P 35/00 (2017.12); C07K 14/245 (2013.01); C07K 14/34 (2013.01); C07K 14/5406 (2013.01); C07K 14/5412 (2013.01); C07K 14/55 (2013.01); C07K 19/00 (2013.01); A61K 38/00 (2013.01); C07K 2319/00 (2013.01); C07K 2319/55 (2013.01); C07K 2319/75 (2013.01)

Citation (search report)

  • [X] WO 9102000 A1 19910221 - SERAGEN INC [US]
  • [X] WO 9101004 A1 19910124 - SERAGEN INC [US]
  • [XP] WO 9119745 A1 19911226 - UNIV HOSPITAL [US]
  • [X] CHARLES F. LEMAISTRE ET AL.: "THERAPEUTIC EFFECTS OF GENETICALLY ENGINEERED TOXIN (DAB486IL-2) IN PATIENT WITH CHRONIC LYMPHOCYTIC LEUKAEMIA.", LANCET THE, vol. 337, 11 May 1991 (1991-05-11), LONDON GB, pages 1124 - 1125
  • [Y] TESUYUKI KIYOKAWA ET AL.: "PROTEIN ENGEERING OF DIPHTERIA-TOXIN-RELATED INTERLEUKIN-2 FUSION TOXINS TO INCREASE CYTOTOXIC POTENCY FOR HIGH-AFFINITY IL-2-RECEPTOR-BEARING TARGET CELLS.", PROTEIN ENGINEERING, vol. 4, no. 4, ENGLAND GB, pages 463 - 468
  • [X] DATABASE BIOSIS BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; & C. F. LEMAISTRE ET AL.: "PHASE I-II EVALUATION OF AN IL-2 RECEPTOR TARGETED FUSION TOXIN DAB-486 IL-2 FOR TREATMENT OF AIDS-ASSOCIATED KAPOSI'S SARCOMA.", ISITITUTO SUP. DI SANITA. VII INTERNATIONAL CONFERENCE ON AIDS: SCIENCE CHALLENGING AIDS; FLORENCE, ITALY, 16 June 1991 (1991-06-16), pages 79
  • [X] NICHOLS, J. C. ET AL: "Development of IL-2-toxin ( DAB486 -IL-2) for human clinical trials in interleukin -2 receptor positive malignancies", ZENTRALBL. BAKTERIOL., SUPPL. (1990), 19(BACT. PROTEIN TOXINS), 479-87 CODEN: ZBASE2
  • [X] BACHA, PATRICIA A. ET AL: "Impact of interleukin -2- receptor -targeted cytotoxins on a unique model of murine interleukin -2- receptor -expressing malignancy", INT. J. CANCER (1991), 49(1), 96-101 CODEN: IJCNAW;ISSN: 0020-7136
  • See references of WO 9220364A1

Designated contracting state (EPC)

AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE

DOCDB simple family (publication)

WO 9220364 A1 19921126; CA 2103258 A1 19921118; EP 0584251 A1 19940302; EP 0584251 A4 19950802; JP H06507900 A 19940908

DOCDB simple family (application)

US 9204093 W 19920515; CA 2103258 A 19920515; EP 92912726 A 19920515; JP 50021493 A 19920515